Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.
Fisher ND, Curfman G. Hypertension—a public health challenge of global proportions. JAMA. 2018;320(17):1757–9.
Zeng Z, Chen J, Xiao C, Chen W. A global view on prevalence of hypertension and human develop index. Ann Global Health. 2020;86(1):67.
Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019;37(6):1148–53.
Mirzaei M, Moayedallaie S, Jabbari L, Mohammadi M. Prevalence of hypertension in Iran 1980–2012: a systematic review. J Tehran Heart Cent. 2016;11(4):159–67.
Eze II, Mbachu CO, Azuogu BN, Ossai E, Unah AI, Akamike IC, et al. Effect of on-site behavioural modification intervention on lifestyle risk factors of hypertension among adult market traders in Abakaliki, Nigeria. Int J Health Promot Edu. 2021;59(1):35–49.
Ostchega Y, Zhang G, Hughes JP, Nwankwo T. Factors associated with hypertension control in US adults using 2017 ACC/AHA guidelines: National Health and Nutrition Examination Survey 1999–2016. Am J Hypertens. 2018;31(8):886–94.
Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism. 2019;92:121–35.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98–107.
Trends in obesity and diabetes across Africa from 1980 to 2014: an analysis of pooled population-based studies. Int J Epidemiol. 2017;46(5):1421–32.
Darbandi M, Pasdar Y, Moradi S, Mohamed HJJ, Hamzeh B, Salimi Y. Discriminatory capacity of anthropometric indices for cardiovascular disease in adults: a systematic review and meta-analysis. Prev Chronic Dis. 2020;17:E131.
Cӑtoi AF, Pârvu AE, Andreicuț AD, Mironiuc A, Crӑciun A, Cӑtoi C, et al. Metabolically healthy versus unhealthy morbidly obese: chronic inflammation, nitro-oxidative stress, and insulin resistance. Nutrients. 2018;10(9):1199.
Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. Liver Int. 2019;39(10):1884–94.
Hsu ARC, Ames SL, Xie B, Peterson DV, Garcia L, Going SB, et al. Incidence of diabetes according to metabolically healthy or unhealthy normal weight or overweight/obesity in postmenopausal women: the Women’s Health Initiative. Menopause. 2020;27(6):640–7.
Blüher M. Metabolically healthy obesity. Endocr Rev. 2020;41(3):405–20.
Pasdar Y, Najafi F, Moradinazar M, Shakiba E, Karim H, Hamzeh B, et al. Cohort profile: Ravansar non-communicable disease cohort study: the first cohort study in a Kurdish population. Int J Epidemiol. 2019;48:682–3.
Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al. Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): rationale, objectives, and design. Am J Epidemiol. 2017;187(4):647–55.
Pasdar Y, Moradi S, Moludi J, Saiedi S, Moradinazar M, Hamzeh B, et al. Waist-to-height ratio is a better discriminator of cardiovascular disease than other anthropometric indicators in Kurdish adults. Sci Rep. 2020;10(1):1–10.
Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–62.
Baek T-H, Lee H-Y, Lim N-K, Park H-Y. Gender differences in the association between socioeconomic status and hypertension incidence: the Korean Genome and Epidemiology Study (KoGES). BMC Public Health. 2015;15(1):1–7.
Luo W, Guo Z, Hao C, Yao X, Zhou Z, Wu M, et al. Interaction of current alcohol consumption and abdominal obesity on hypertension risk. Physiol Behav. 2013;122:182–6.
Gus M, Fuchs SC, Moreira LB, Moraes RS, Wiehe M, Silva AF, et al. Association between different measurements of obesity and the incidence of hypertension. Am J Hypertens. 2004;17(1):50–3.
Chen Z, Li S, Wang X, Zhang L, Shao L, Tian Y, et al. The incidence of hypertension, overweight, and obesity and relationship with cardiovascular events among middle-aged Chinese: 6 years follow-up results. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(1):47–53.
Leggio M, Lombardi M, Caldarone E, Severi P, D’emidio S, Armeni M, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertens Res. 2017;40(12):947–63.
Ruilope LM, Nunes Filho A, Nadruz W Jr, Rosales FR, Verdejo-Paris J. Obesity and hypertension in Latin America: current perspectives. Hipertension y riesgo vascular. 2018;35(2):70–6.
Pasdar Y, Moradi S, Hamzeh B, Najafi F, Nachvak SM, Mostafai R, et al. The validity of resting energy expenditure predictive equations in adults with central obesity: a sub-sample of the RaNCD cohort study. Nutr Health. 2019;25(3):217–24.
Hinnouho G-M, Czernichow S, Dugravot A, Batty GD, Kivimaki M, Singh-Manoux A. Metabolically healthy obesity and risk of mortality: does the definition of metabolic health matter? Diabetes Care. 2013;36(8):2294–300.
Fingeret M, Marques-Vidal P, Vollenweider P. Incidence of type 2 diabetes, hypertension, and dyslipidemia in metabolically healthy obese and non-obese. Nutr Metab Cardiovasc Dis. 2018;28(10):1036–44.
Yuan Y, Mu J-J, Chu C, Zheng W-L, Wang Y, Hu J-W, et al. Effect of metabolically healthy obesity on the development of arterial stiffness: a prospective cohort study. Nutr Metab. 2020;17(1):1–10.
Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, et al. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 2015;10(4):578–83.
Gilardini L, Zambon A, Soranna D, Croci M, Invitti C. Predictors of the transition from metabolically healthy obesity to unhealthy obesity. Eating Weight Disord Stud Anorex Bulim Obes. 2018;23(6):739–44.
Zhang N, Chen Y, Guo X, Sun G, Dai D, Sun Y. Metabolic abnormalities, but not metabolically healthy obesity, are associated with left ventricular hypertrophy. Heart Lung Circ. 2017;26(3):251–7.
Mongraw-Chaffin M, Foster MC, Anderson CA, Burke GL, Haq N, Kalyani RR, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71(17):1857–65.
Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7.
Pasdar Y, Moradi S, Abdollahzad H, Hamzeh B, Najafi F, Nachvak SM, et al. Accuracy of waist to hip ratio calculated by bioelectric impedance device in the Ravansar non-communicable disease cohort study. Top Clin Nutr. 2019;34(4):269–76.
Jiang P, Ma D, Wang X, Wang Y, Bi Y, Yang J, et al. Astragaloside IV prevents obesity-associated hypertension by improving pro-inflammatory reaction and leptin resistance. Mol Cell. 2018;41(3):244.
Lambert EA, Straznicky NE, Dixon JB, Lambert GW. Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity? Am J Physiol Heart Circ Physiol. 2015;309(2):H244–58.
Aronow WS. Association of obesity with hypertension. Ann Transl Med. 2017;5(17):350.
Cwynar M, Gąsowski J, Gryglewska B, Głuszewska A, Kwater A, Królczyk J, et al. Insulin resistance and renal sodium handling influence arterial stiffness in hypertensive patients with prevailing sodium intake. Am J Hypertens. 2019;32(9):848–57.
Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension. 2006;47(6):1108–16.
De Boer MP, Meijer RI, Wijnstok NJ, Jonk AM, Houben AJ, Stehouwer CD, et al. Microvascular dysfunction: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. Microcirculation. 2012;19(1):5–18.
Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int. 2015;87(3):497–9.